Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Li XuanQi-Fa LiuPublished in: Journal of hematology & oncology (2021)
Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- acute lymphoblastic leukemia
- end stage renal disease
- ejection fraction
- patients undergoing
- newly diagnosed
- prognostic factors
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- smoking cessation
- hematopoietic stem cell
- free survival